No data available
Protogenia Consulting Ltd offers non-clinical and early clinical development consultancy services, with more than 15 years' outsourcing and project management experience gained through virtual and mid-sized pharmaceutical companies. The services offered include: strategic planning to enable early clinical development and product registration; non-clinical and clinical project management; regulatory submission writing/review/sign-off (e.g. CTA/IND, MAA/NDA, IMPD and IB); and CRO selection and study management – clinical (up to Phase 2) and non-clinical (toxicology, safety pharmacology, ADME, bioanalysis). In addition, we have a broad network of contacts, for expert advice on IP, CMC, analytical services, regulatory affairs and quality assurance.
Qkine was founded in 2016 to produce high-quality growth factors for use in regenerative medicine applications. The company builds on expertise in protein purification and structural biology developed at University of Cambrige and collaborations with the Cambridge stem cell community. We address the need for high-quality growth factors for regenerative medicine and innovate to tackle challenges in stem cell science.
QRC Consultants, experienced professionals dedicated to providing high quality, cost-effective support to biopharmaceutical companies in early clinical development. We offer technical expertise with strengths including: understanding of the regulatory environment governing clinical trials globally; regulatory agency meetings and submissions – trial management, and monitoring and audit of trials; and small molecules, biological and advanced therapies. Services include: quality assurance – setup and maintenance of QMS, GCP audits and agency inspection preparation; regulatory affairs – technical document writing, SME and EU legal representative services, and bespoke procedural and GCP training; and clinical trial support – project management and monitoring.
The Quadram Institute is an interdisciplinary research centre capitalising on the academic excellence and clinical expertise of the Norwich Research Park. Its mission is to understand how food and the gut microbiota link to the promotion of health and the prevention of diet and age-related diseases. It brings together fundamental and translational science with a clinical research facility for human trials and one of Europe’s largest gastrointestinal endoscopy units. The Quadram Institute is accelerating innovation by synergising interactions between basic and clinical research, delivering a step-change in the understanding of the role of food and the microbiome on health.
By understanding biology and empowering action, Quantum-Si aims to improve human health. We provide researchers, scientists and clinicians with a convenient solution that reveals in-depth, proteomic insight in an easy-to-use accessible workflow. Our technology allows them to expand their understanding of cell biology and disease by uncovering what is there and not what could be there, which opens the door to the development of new diagnostics and discovery of novel, lifesaving drugs.
QMB is the largest purpose-built space in London for companies in science and technology, and the only centre to offer follow-on growth space for companies emerging from incubator space.. . Accommodation is available in flexible suite sizes from 500 square feet with flexible competitively-priced leases to other London based offerings. The flexibility of the centre means space can be easily reconfigured in response to meet a tenant's needs.
Queen May Innovation Ltd (QMI), is the wholly owned technology transfer subsidiary of Queen Mary, University of London. QMI is responsible for identifying, protecting and commercialising novel technologies in medicine and dentistry, healthcare, science and engineering. QMI manages a large and varied portfolio of licensed technologies and spin-out companies. With around 16,900 students, 3800 staff and an annual turnover of £300m, we are one of the biggest University of London colleges. The London School of Medicine and Dentistry faculty focuses on: translational research, cancer, cardiac, dentistry, inflammation, endocrinology/metabolism, immunology and infectious diseases, genomics, neuroscience, gastroenterology, epidemiology and primary care.
The Business Development Office provides access to Queen Mary University of London cutting-edge capabilities and state-of–the-art facilities. Our team of Business Development Managers will identify relevant academic expertise to meet your commercial requirements through collaborative research, contract research and consultancy.
Quotient Sciences are dedicated to accelerating the development of new drugs for patients around the world. They provide formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via their Translational Pharmaceutics® platform.. . For more than 30 years, Quotient Sciences has brought innovation to early drug development programs for pharmaceutical companies worldwide. At the company’s purpose built facilities, real-time manufacturing of all types of dosage forms is co-located with its clinical pharmacology unit to maximise flexibility, speed and cost savings for clients.